FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

HIGGINS JOHN L		 2. Issuer Name and Ticker or Trading Symbol

BIO-TECHNE Corp [ TECH ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

11085 NORTH TORREY PINES ROAD, SUITE 300		 3. Date of Earliest Transaction (MM/DD/YYYY)

8/10/2022
(Street)

LA JOLLA, CA 92037
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 8/10/2022  M  3400 A$66.90 8006 D  
Common Stock 8/10/2022  S  900 D$373.9918 (2)7106 D  
Common Stock 8/10/2022  S  100 D$374.8950 (3)7006 D  
Common Stock 8/10/2022  S  992 D$380.153 (4)6014 D  
Common Stock 8/11/2022  S  504 D$385.4694 (5)5510 D  
Common Stock 8/11/2022  S  8 D$380.71 5502 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $66.90 8/10/2022  M     3400  10/25/2012 10/24/2022 Common Stock 3400 $0 0 D  
Stock Option (right to buy) $87.3900           10/31/2013 10/30/2023 Common Stock 4000  4000 D  
Stock Option (right to buy) $91.7800           10/30/2014 10/30/2024 Common Stock 4000  4000 D  
Stock Option (right to buy) $87.3400           10/29/2016 10/28/2025 Common Stock 4260  4260 D  
Stock Option (right to buy) $101.1900           10/26/2017 10/26/2026 Common Stock 3985  3985 D  
Stock Option (right to buy) $125.0500           10/25/2018 10/27/2027 Common Stock 3125  3125 D  
Stock Option (right to buy) $179.8400           10/24/2019 10/25/2028 Common Stock 1898  1898 D  
Stock Option (right to buy) $201.6400           10/24/2020 10/24/2029 Common Stock 2011  2011 D  
Stock Option (right to buy) $255.6900           10/28/2021 10/29/2030 Common Stock 1507  1507 D  
Stock Option (right to buy) $515.2400            (1)10/28/2031 Common Stock 633  633 D  
Explanation of Responses:
(1) The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders.
(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 373.8600 to 374.3300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 374.8950 to 374.9000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 380.0000 to 380.4400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 385.2900 to 385.8900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
HIGGINS JOHN L
11085 NORTH TORREY PINES ROAD
SUITE 300
LA JOLLA, CA 92037		X
Signatures
/s/ Brenda S. Furlow, Attorney-in-Fact8/12/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Bio Techne Charts.
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Bio Techne Charts.